Cephalon Inc. acquired CIMA Labs Inc. for approximately $515 million ($34.00 per share), gaining CIMA's OraVescent fentanyl drug-delivery platform to extend Cephalon's Actiq breakthrough-cancer-pain franchise. To resolve FTC competitive concerns, Cephalon agreed to license a generic version of Actiq to Barr Laboratories. The transaction closed in August 2004.